Commission Implementing Decision (EU) 2026/1420 of 30 June 2026 on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council